Fox Rothschild was featured in the Law.com article, "Deal Watch: Energy, Pharma Deals Usher in Labor Day M&A." Full text can be found in the September 4, 2015, issue, but a synopsis is below.
Philadelphia-based pharmaceutical company Lannett, assisted by Fox Rothschild LLP, will pay $1.23 billion to buy Kremers—the U.S. generics-focused subsidiary of Belgian drugmaker UCB SA. The 18-product portfolio acquired by Lannett includes methylphenidate hydrochloride, a drug used to treat attention deficit hyperactivity disorder. The deal is expected to close in the fourth quarter of this year.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
